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Dry powder inhalers (DPIs) are widely and increasingly used in clinical practice because they represent a substantial
advancement in inhalation technology. The effectiveness of a powdered drug to inhale depends on the inspiratory
flow rate generated by the patient and on the turbulence produced by the intrinsic resistance of the DPI. While the
inspiratory flow is variable with the patient’s ability and conditions, the turbulence is differently sized within each
device because depending of its technical design. There are higher - medium-, and low-resistance devices. With
low-resistance DPIs, the disaggregation and the microdispersion of the drug highly depend on the patient’s
inhalation airflow rate, because the role of the resistance-induced turbulence is obviously negligible in these
cases. This flow-rate dependency is minimized in the presence of a sufficient regimen of turbulence as in the case
of medium-resistance DPIs. Both the disaggregation and the micro-dispersion of the powdered drug are optimized in
these circumstances even in the absence of a maximal inspiratory flow rate.
The low resistance DPIs should not be regarded as the best performer DPIs because their intrinsic low-resistance
regimen requires a higher inspiratory airflow rate and effort, which frequently cannot be achieved by subjects suffering
from a disease-induced airflow limitation.
Only when the ratio between the inhalation flow rate and the DPI intrinsic resistance is balanced, the speed of the
particulate, the distribution of the drug within the lung, and the variability of the effective inhaled dose are optimized.
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effectivenessIntroduction
The delivery of pharmacological agents by inhalation is a
critical issue in obstructive airway diseases (Bronchial
Asthma and Chronic Obstructive Pulmonary Disease
(COPD)). It represents a major component of their
therapeutic management because inhaled drugs are tar-
geting the lungs directly, consenting a lower dose to-
gether with a quick onset of action, and a better
therapeutic index [1,2].
Several effective molecules have been developed in the
last decades, but their true effectiveness in real life can
be affected and modulated substantially by the device
used for inhalation [3-5].Correspondence: robertodalnegro@gmail.com
1National Center for Respiratory Pharmacoeconomics and
Pharmacoepidemiology - CESFAR, Verona, Italy
2Research & Clinical Governance, Verona, Italy
© 2015 Dal Negro; licensee BioMed Central. T
Commons Attribution License (http://creativec




An increasing number of inhalation devices have been
engineered in the same period, either for single or com-
bined molecules. However, it was assumed since long
ago that the ideal device should be:
1) effective: such as, able to consent the inhalation of a
sufficient fraction of drug with a particle size ≤ 6 μ,
independently of the patient’s inspiratory flow;
2) reproducible: such as, able to always consent the
inhalation of the same drug amount, also in terms of
its respirable fraction;
3) precise: such as, able to consent to know at any
moment the amount (or the n. of doses) of the drug
remaining in the device, and whether or not the
inhalation was correctly performed: thus the need
for providing DPIs of a “dose counter” and of a
“double-dosing protection counter”, in order to avoidhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The main classes of DPIs, based on their intrinsic
resistance and pressure drop across the device
Pressure drop across the device
Low resistance DPIs <5 Mbar 1/2 L/min −1
Medium resistance DPIs 5-10 Mbar 1/2 L/min −1
High resistance DPIs >10 Mbar 1/2 L/min −1
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sure of having taken the previous one [6];
4) stable: such as, able to protect the drug(s) contained
from the effects of temperature and/or humidity
changes;
5) confortable: such as, easy to use in different
circumstances (particularly in critical conditions),
and possibly containing several doses of the drug(s)
for a long-term use;
6) versatile: such as, it should consent the use of other
drugs by inhalation;
7) environmental compatible, such as not containing
chemical contaminants;
8) affordable: such as, of acceptable cost, and possibly
rechargeable [2].
The DPIs’ family
Independently of wet nebulizers, pocket devices can be
basically grouped in three major classes: a) the Metered
Dose Inhalers (MDIs), still largely used for single and
combined molecules, and which need a propellant for
the dose delivery; b) the Dry Powder Inhalers (DPIs),
which do not require any propellant, and are increas-
ingly prescribed for single and combined molecules; c)
the Soft Mist Inhalers (SMIs), at present consisting in
only one device for only one molecule (Respimat for
Tiotropium bromide).
DPIs, even if widely variable in design, definitively rep-
resent a substantial improvement in the inhalation ther-
apy because they fit the majority of the above mentioned
requirements. In particular, they eliminate the use of
propellants; simplify the inhalation technique; reduce
the patient’s cooperation and improve the patient’s com-
pliance to treatment; favour a higher deposition of drugs
within the lungs; reduce the variability of the inhaled
dose; reduce the incidence of both local and systemic side
effects, and finally ameliorate the consistency of the dose
and then the outcomes substantially [7-10]. Further-
more, most advanced DPIs also fitted the most sophis-
ticated patients’ requirements in terms of minimization
of the number of actions needed for preparing the
actuation.
Main characteristics of DPIs
Basically, DPIs can be differentiated according to their
intrinsic resistive regimen, such as a constant which de-
pends on the original constructive design of each device,
and which is evaluated by measuring the extent of pres-
sure drop across the device itself (Table 1).
When rewievig the most common DPIs used in clin-
ical practice, the HandyHaler; the Easyhaler and the
Twisthaler belong to the class of the higher-resistance
devices, while the Turbohaler; the Accuhaler/Diskus, the
Ellipta, the Novolizer, and the Genuair belong to thegroup of medium-resistance devices, and the Aerolizer
and the Breezhaler belong to the class of low-resistance
devices [11,12].
In general terms, the performance of each DPI can be af-
fected by only two main driving forces: 1) the inspiratory
flow generated by the patient, and 2) the turbulence pro-
duced inside the device, which uniquely depends by its ori-
ginal technical characteristics [1,11]. These are the only
two factors able to affect the disaggregation of the pow-
dered drug dose, the diameter of the particles to inhale, the
consistency and the variability of the dose, substantially.
In particular, the inspiratory airflow generated by the pa-
tient represents the only active force (a passive force for
the device) able to produce the micro-dispersion (even if
differently sized for each device) of the powdered drug to
inhale. On the other hand, the extent of the patient’s in-
spiratory airflow depends on the patient’s airway and lung
conditions, and, partially, on the intrinsic resistive regimen
of the device.
During an inspiratory manoeuvre, the right balance
between these two forces represents the critical factor
which decides the true effectiveness of the couple “mol-
ecule-device”. Higher the airflow, higher the powder dis-
persion generating a fine particulate, even if such a high
airflow leads to a higher impaction losses in the prox-
imal airways and, consequently, to a lower dose reaching
peripheral airways [2,11]. On the other hand, a lower air-
flow consents a deeper lung deposition of the powdered
drug, even if a too low airflow (as that one existing in
the severest patients) can limit deposition by affecting
powder disaggregation and dispersion.
Obviously, changes in these two forces can be achieved
only by changing the airflow characteristics or the ori-
ginal DPI design.
In particular, when using a medium-resistance DPI,
both the disaggregation and the micro-dispersion of the
powdered drug are relatively independent of the pa-
tient’s inspiratory airflow because the driving force de-
pending on the intrinsic resistance of the DPI itself is
able to produce per sè the turbulence required for an
effective drug microdispersion. In these cases, the speed
of the particulate is lower, the distribution of the drug
is much better within the lung, and the variability of
the effective inhaled dose is quite lower, thus leading to
a drug delivery which is more fitting to the correspond-
ing original claim [13].
Table 2 Differences in intrinsic resistance and in inspiratory
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the only driving force for the disaggregation and the
microdispersion of the drug to inhale is represented by
the patient’s inhalation airflow rate (the role of the
resistance-induced turbulence is obviously negligible in
these cases), which only depends, even if at a different ex-
tent, on the patient’s airflow limitation and in addition,
on his disease severity. As a consequence, the required
regimen of turbulence can be achieved only by increas-
ing the inhalation airflow, which nevertheless fre-
quently represents the main critical limitation for
airway obstructive patients. In these circumstances, the
variability in the dose consistency is higher and the ef-
fective inhaled dose can be far from the original claim,
also due to the higher oro-pharingeal impact of the
powdered drug.
Actually, we are in the presence of a “conceptual mis-
understanding” which is crucial for interpreting the
events and for deciding which DPI is more convenient
for the patient in real-life. In other words, the “low re-
sistance DPIs” should not be mandatory associated to
the concept of “the most effective DPIs” because just in
these cases patients are required for a higher inspiratory
performance, which frequently cannot be achieved by
patients affected by a disease-induced airflow limitation.
Unfortunately, these concepts were not sufficiently
clarified and popularized in general practice, and they
were progressively neglected and practically left to the
wrong simplistic interpretation of the term “low-resist-
ance”, which spontaneously recalls per sè the principle of
“easiness of use”, particularly in non expert prescribers.
Also the reluctance of producers to better explain or
characterize their device played a crucial role in neglect-
ing these aspects.
Presumably, the real-life scenario is getting increas-
ingly confusing in the near future because, further to the
numerous DPIs already available for therapeutic pur-
poses, some novel devices are entering the market. An
increasing range of intrinsic resistance regimens should
then be considered, because the DPIs’ performances will
further vary between each other in terms of therapeutic
effectiveness also substantially.
A technical review on DPIs currently available on the
market has been recently carried out in order to com-
pare in standard conditions (at a defined pressure point
of 4 kPa) their intrinsic characteristics in terms of in-
spiratory device resistance, of inspiratory flow rate and
corresponding pressure drop, and of their performance
variability [11]. In total agreement with the concept pre-
viously mentioned, the low-resistance DPIs confirmed
those requiring the highest inspiratory flow rates for
consenting an effective actuation and those character-
ized by the highest variability in delivery of respirable
fraction of the drug (Table 2).In particular, the Breezhaler, which is the DPI device
at present characterized by the lowest intrinsic resistance
(such as, 0.017 kPa0.5 L/min), proved to require the
highest inspiratory flow rate at an average of 111 L/min
(min 102 and max 117 L/min). Moreover, it showed a
mean pressure drop of 2.5-4 kPa, and a large variability
in the dose delivery, by a standard deviation higher than
4% [11]. An equivalent performance has been assessed
for other DPIs with the same intrinsic characteristics (i.
e. the Aerolizer) (Table 2).
Other DPIs which are characterized by a medium in-
trinsic resistance consent a better performance from this
point of view. Actually, the Novolizer; the Accuhaler/
Diskus, the Genuair, which have an intrinsic resistance
of 0.027; 0.027, and 0.031, respectively, confirmed to re-
quire a much lower inspiratory flow rate for an effective
actuation (such as: 72; 72, and 64 L/min) (Table 2). The
corresponding pressure drop was ranging 6.6-9.5 kPa,
with the lowest rate of variability, by a standard devi-
ation lower than 1% in the case of Genuair [11].
Finally, high resistance DPIs (ranging 0.035-0.058
kPa0.5 L/min) even if allowing a lower inspiratory flow
rate, proved to affect particle generation and dispersion
of powdered drug substantially [14,15].
Conclusions
The critical factors driving the therapeutic effectiveness
of a respiratory drug assumed through a DPI are repre-
sented by the constructive constants of the device and
by the generation of an inhalation airflow rate sufficient
to trigger the dose and disaggregate the drug, thus pro-
ducing a particulate of optimal size, and able to reach
the therapeutic targets within the airways.
It should be taken into account because a proportion
of patients is unable to afford an effective inhalation in
real life. Particularly in COPD, it mainly depends on lim-
itations in their cognition performance [16], on their
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ent airway impairment. On the other hand, the extent of
this phenomenon has been confirmed to change accord-
ing to the prescribed DPI [16,17].
The particle size is another critical point for the effect-
iveness of treatment because it affects the respirable
fraction and the lung deposition of the inhaled drug.
The inhalation speed can also play a role because while
small particles (1–2 μ in diameter) show a comparable
effect independently of the inhalation speed, larger parti-
cles (3–6 μ in diameter) are more effective when inhaled
at a lower speed [18-20]. This aspect has been overcome
by the use of DPIs which are provided with a trigger
valve which consents the release of the powdered drug
only after a preset airflow rate (35 L/min) has been
achieved [21,22,23].
In conclusion, the effectiveness of a powdered drug to
inhale mainly depends on the inspiratory flow rate gen-
erated by the patient and on the intrinsic resistance of
the DPI device. These two forces affect the dose
utilization, both the powder disaggregation and disper-
sion, its penetration into the airways, and finally the effi-
cacy of treatment.
An increasing number of DPIs are available for differ-
ent drugs, and they are differently characterized in terms
of their intrinsic constants, even if wrong assumptions
are still diffuse concerning the therapeutical perform-
ance of DPIs in real life. In other words, while low-
resistance DPIs are still regarded as the easiest and the
most comfortable devices for the patient, they instead
require a high inhalation airflow rate to the patient, not
always achievable. The reason is that the role of the
other possible force involved in drug deagglomeration
(such as the DPI intrinsic resistance) is negligible in
these circumstances, and the whole effect is merely de-
pending on the patient’s high flow rate. Actually, when
using this kind of DPIs, the patient has sometimes to re-
peat the inhalation manoeuvre in order to inhale com-
pletely the dose of the powdered drug in the capsule,
particularly the most compromised patients.
Differently, medium-resistance DPIs require a lower
inhalation flow rate to the patient because the turbu-
lence generated by the intrinsic resistance regimen oper-
ating inside these devices contribute substantially to the
drug deagglomeration and to the effective production of
particulate, thus reducing the impaction losses in the
upper airways and reducing the aerodynamic variability
of the particulate itself.
Medium-resistance DPIs combine the advantage of re-
quiring more achieveable flow rates with that of produ-
cing an effective respirable fraction of the drug to inhale.
These characteristics are particularly relevant in terms of
real-life utilization by compromised and flow-limited pa-
tients who can find in the generation of high inspiratoryflow rates the major limit in the effectiveness of their re-
spiratory treatment.
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